Trials / Completed
CompletedNCT02719184
Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD (Chronic Obstructive Pulmonary Disease)
Observational Study in Healthy Subjects and Patients With COPD to Assess the Relationship Between Clinical, Imaging and Biomarker Measurements, and Progression of Emphysema Over Three Years [FOOTPRINTS®].
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 463 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 40 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The study will include 60 healthy subjects (ex-smoker without any airflow limitation), 125 COPD GOLD (global initiative for chronic obstructive lung disease) I , 125 COPD GOLD II, 125 COPD GOLD III and up to 20 patients with COPD and A1AT (Alpha1-Antitrypsin) deficiency (ZZ genotype). Soluble and imaging biomarkers will be investigated addressing different aspects of disease pathways postulated to be relevant for COPD progression.
Conditions
Timeline
- Start date
- 2016-04-13
- Primary completion
- 2021-06-14
- Completion
- 2021-06-14
- First posted
- 2016-03-25
- Last updated
- 2024-08-16
- Results posted
- 2024-08-16
Locations
51 sites across 12 countries: United States, Belgium, Canada, Denmark, Finland, Germany, Japan, Poland, South Korea, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT02719184. Inclusion in this directory is not an endorsement.